MedTrace Logo

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS

NCT01702987 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-04-17

Study results available
· View outcomes & findings →

Summary

It is our primary hypothesis that statin drugs impair skeletal muscle mitochondrial function and that ubiquinol (the reduced active form of CoQ10) supplementation will block impairment of PCr recovery kinetics in patients using statins. The investigators propose a pilot study to extend our research to examine PCr recovery kinetics in 20 statin users randomized in a parallel arm study to either ubiquinol or placebo over 4 weeks.

Conditions

Interventions

DIETARY_SUPPLEMENT

ubiquinol

ubiquinol supplementation was given for 1 month to 12 patients

DIETARY_SUPPLEMENT

placebo

placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients

DRUG

statin

statin was given for 1 month to 21 patients

Sponsors & Collaborators

Principal Investigators

  • Jim S Wu, MD · Beth Israel Deaconess

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702987 on ClinicalTrials.gov